BRANDI RAGSDALE: Open Payments
NPI 1760161665 · NEW ALBANY, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,218 in 88 payments from 22 companies in 2025. Trend: 2023 $0 · 2024 $1,192 · 2025 $2,218
Food & beverage: $2,199Education: $20
| Company | Payments | Amount |
|---|---|---|
| Travere Therapeutics, Inc. | 16 | $547 |
| Amgen Inc. | 10 | $265 |
| Alexion Pharmaceuticals, Inc. | 8 | $219 |
| Otsuka America Pharmaceutical, Inc. | 10 | $202 |
| Calliditas Therapeutics US Inc. | 7 | $178 |
| Vifor Pharma, Inc. | 5 | $150 |
| Ardelyx, Inc. | 7 | $135 |
| AstraZeneca Pharmaceuticals LP | 6 | $100 |
| SCPHARMACEUTICALS INC. | 3 | $92 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $53 |
Products named: TAVNEOS, ULTOMIRIS, TARPEYO, JYNARQUE, Veltassa, Filspari, IBSRELA, FARXIGA.
Industry payments across IN — which companies pay providers there.
